How childhood lead exposure harms the developing brain and mental health
Neurobiology of lead exposure and risk of psychiatric disease
The team is testing whether a brain‑protective supplement (7,8‑dihydroxyflavone) can reduce learning, behavior, and brain‑circuit problems caused by childhood lead exposure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida International University NIH-funded |
| Lab location | 1 site (Miami, United States) |
| Project ID | NIH-11231697 on NIH RePORTER |
What this research studies
Researchers use animal models that mimic childhood lead exposure to see how early lead changes specific brain cells and circuits. They focus on parvalbumin-positive GABAergic interneurons and measure regional brain volume, connectivity, and behavior to map how those changes lead to cognitive and sensorimotor problems. The team will give 7,8‑dihydroxyflavone, a blood–brain‑barrier permeable BDNF mimic, to test whether it can prevent or reverse cellular, network, and behavioral deficits. Results are intended to fill knowledge gaps and guide future treatments for people exposed to lead in childhood.
Who could benefit from this research
Good fit: People who had significant lead exposure in early childhood and now have persistent cognitive, behavioral, or psychiatric symptoms would be the most relevant candidates for related human research or future trials.
Not a fit: Individuals without a history of early-life lead exposure or whose symptoms stem from other causes are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this work could point to a treatment that prevents or reduces long‑term cognitive and psychiatric problems after childhood lead exposure.
How similar studies have performed: Related BDNF‑mimetic compounds like 7,8‑DHF have shown benefit in other animal models of brain injury or dysfunction, but human testing for lead‑related effects is limited.
Where this research is happening
Miami, United States
- Florida International University — Miami, United States (Active)
Researchers
- Principal investigator: Guilarte, Tomas R — Florida International University
- Study coordinator: Guilarte, Tomas R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.